

ASX ANNOUNCEMENT

21 May 2025

Biome announces appointment of healthcare sector leader Geoff Sam OAM as Chairman of the Board of Directors

Microbiome health company **Biome Australia Limited** (ASX: BIO) (*'Biome'* or *'the company'*) is pleased to announce the appointment of Geoff Sam as Chair of *Biome Australia's* Board of Directors following the voluntary resignation of Ilario Faenza effective as of 6pm Tuesday 20th May, 2025. Ilario has resigned from the board for personal reasons, including to support his executive role as CEO of Harvest Technology Group (ASX:HTG).

The Board wishes to thank Ilario for his five-year leadership as chair, which has been marked by significant company growth. *Biome* extends its appreciation for his dedicated support and guidance to the managing director and board during his tenure. Ilario said, *"I am confident that Geoff is well-positioned to support the managing director and the board with its next phase of growth."*

Geoff Sam brings extensive industry-specific knowledge and experience, including expertise in healthcare and pharmaceutical manufacturing to his role as chair of *Biome*. His extensive leadership experience is augmented by qualifications including Bachelor of Commerce (Accounting and Finance, UNSW), Master of Health Administration (UNSW), and a Master of Arts (Economics and Social Studies, University of Manchester). Geoff is also a Fellow of the Australian Institute of Company Directors.

Geoff's extensive business experience and industry network will be critical in supporting *Biome's* management team in the ongoing commercial development of *Biome's Activated Probiotics* and *Activated Therapeutics*, both locally and abroad. They will also be highly beneficial in guiding *Biome* through the Vision 27 strategic plan and beyond, particularly in achieving its key objective of optimising manufacturing processes.

For personal use only

Following the confirmation of his appointment as chair of Biome Australia's Board of Directors, Geoff Sam said:

"I am thrilled to take on the chair's role on the Biome board and being able to offer my support and guidance to Blair and the management team. Biome has achieved outstanding growth to date and I thank Ilario for his contribution to this outcome. There are great opportunities in process now and our goal is to convert these to revenue and profit. As a significant shareholder in Biome, I feel well aligned to the shareholder base and feel confident about what lies ahead."

Biome Australia's Managing Director and Founder, Blair Vega Norfolk also commented:

"It is with gratitude that I thank Ilario for his time as chair and his service to the Biome board and shareholders over these past five years. His advice has been a valued support through various phases of the business, including our IPO. I turn to welcoming Geoff, with excitement on what is to come. Geoff has got to know the business as a major shareholder for more than five years and been someone I have admired from afar. Geoff's business success in healthcare is something we look forward to drawing advice from and I am very happy to put my full support behind him in the execution of Vision 27 and beyond."

-ENDS-

Approved for release by the Biome Australia Board of Directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: [Activated Probiotics](#).



For personal use only

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Rechelle Friend

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or



For personal use only

results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.

For personal use only



Biome Australia Trading Pty Ltd
192-194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014

